SYRACUSE, N.Y.-SUNY Upstate Medical University Hospital said late last month it has called off plans to collaborate with 418-bed Crouse Hospital in a deal that would have "functionally integrated" bankrupt Crouse with the state-run university hospital. SUNY officials said its reasons were union opposition to the integration and Crouse's apparent intention to emerge from bankruptcy with a "stand-alone" operating plan. "Clearly, SUNY Upstate cannot participate in the proposed collaboration plan without the partnership of Crouse Hospital," SUNY officials said in a written statement. Crouse officials said they were "mystified" as to why 356-bed SUNY issued the statement. The plan called for a collaboration in which the hospitals would remain legally separate but would operate under the same management.
PHILADELPHIA-Tenet Healthcare Corp., Santa Barbara, Calif., signed a letter of intent last month to buy 129-bed Roxborough Memorial Hospital, signaling the for-profit hospital chain's readiness to expand its Philadelphia operations. Since purchasing seven hospitals from bankrupt Allegheny Health, Education and Research Foundation more than three years ago, Tenet has "completed a rather miraculous turnaround" of the facilities, Tenet spokesman Harry Anderson said. The hospitals for the most part are focused on high-end care. The open-ended letter of intent involving Roxborough Memorial is a preliminary step toward a purchase agreement and doesn't guarantee a deal will be completed, Anderson said.
BOSTON-A federal appeals court has overturned an $8 million jury award in the case of two brain tumor patients who died more than four decades ago during experimental nuclear treatments partially funded by the federal government. The 1st U.S. Circuit Court of Appeals, in a decision released last month, said key witnesses against Massachusetts General Hospital and neurosurgeon William Sweet, M.D., relied improperly on information published after the 1961 procedures that led to the deaths of the two patients. It said there was insufficient evidence presented at Sweet's trial in 1999 to support the jury's finding that the patients' deaths were linked to boron neutron capture therapy, a procedure partly funded by the U.S. Atomic Energy Commission. Sweet died in January 2001 at the age of 90.